| Dr Jessica Olander, MD | |
|
905 W 124th Ave Ste 170, Westminster, CO 80234-1716 | |
| (303) 442-6647 | |
| (303) 442-2696 |
| Full Name | Dr Jessica Olander |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 15 Years |
| Location | 905 W 124th Ave Ste 170, Westminster, Colorado |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1659515658 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 52384 (Colorado) | Secondary |
| 207ND0101X | Dermatology - Mohs-micrographic Surgery | 52384 (Colorado) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Dermatology Specialists Of Boulder Pc | 3678668761 | 12 |
| Core Dermatology Pllc | 8921347998 | 4 |
News Archive
"Secretary of State Hillary Rodham Clinton said Tuesday she resents criticism of the U.S. effort to help stricken Haiti and pledged to redouble efforts to help survivors of the Jan. 12 earthquake," the Associated Press/CBSNews.com reports. "I deeply resent those who attack our country, the generosity of our people and the leadership of our president in trying to respond to historically disastrous conditions after the earthquake," she said.
Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced enrollment of the first patient in the company's JETSTREAM G3 Calcium Study, a prospective, single-arm, multi-center registry to evaluate the treatment effects of the JETSTREAM G3 System in patients with moderate to severely calcified peripheral artery disease.
News outlets report on the political dilemma involved with Provenge — a cancer drug — as well as the impact that Makena — the medicine that can prevent preterm births — could have on the nation's high health care costs.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
› Verified 1 days ago
| Entity Name | Dermatology Specialists Of Boulder Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053449306 PECOS PAC ID: 3678668761 Enrollment ID: O20071004000308 |
News Archive
"Secretary of State Hillary Rodham Clinton said Tuesday she resents criticism of the U.S. effort to help stricken Haiti and pledged to redouble efforts to help survivors of the Jan. 12 earthquake," the Associated Press/CBSNews.com reports. "I deeply resent those who attack our country, the generosity of our people and the leadership of our president in trying to respond to historically disastrous conditions after the earthquake," she said.
Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced enrollment of the first patient in the company's JETSTREAM G3 Calcium Study, a prospective, single-arm, multi-center registry to evaluate the treatment effects of the JETSTREAM G3 System in patients with moderate to severely calcified peripheral artery disease.
News outlets report on the political dilemma involved with Provenge — a cancer drug — as well as the impact that Makena — the medicine that can prevent preterm births — could have on the nation's high health care costs.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
› Verified 1 days ago
| Entity Name | Core Dermatology Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790255313 PECOS PAC ID: 8921347998 Enrollment ID: O20190308002242 |
News Archive
"Secretary of State Hillary Rodham Clinton said Tuesday she resents criticism of the U.S. effort to help stricken Haiti and pledged to redouble efforts to help survivors of the Jan. 12 earthquake," the Associated Press/CBSNews.com reports. "I deeply resent those who attack our country, the generosity of our people and the leadership of our president in trying to respond to historically disastrous conditions after the earthquake," she said.
Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced enrollment of the first patient in the company's JETSTREAM G3 Calcium Study, a prospective, single-arm, multi-center registry to evaluate the treatment effects of the JETSTREAM G3 System in patients with moderate to severely calcified peripheral artery disease.
News outlets report on the political dilemma involved with Provenge — a cancer drug — as well as the impact that Makena — the medicine that can prevent preterm births — could have on the nation's high health care costs.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jessica Olander, MD 1056 S 88th St, Louisville, CO 80027-9460 Ph: (303) 442-6647 | Dr Jessica Olander, MD 905 W 124th Ave Ste 170, Westminster, CO 80234-1716 Ph: (303) 442-6647 |
News Archive
"Secretary of State Hillary Rodham Clinton said Tuesday she resents criticism of the U.S. effort to help stricken Haiti and pledged to redouble efforts to help survivors of the Jan. 12 earthquake," the Associated Press/CBSNews.com reports. "I deeply resent those who attack our country, the generosity of our people and the leadership of our president in trying to respond to historically disastrous conditions after the earthquake," she said.
Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced enrollment of the first patient in the company's JETSTREAM G3 Calcium Study, a prospective, single-arm, multi-center registry to evaluate the treatment effects of the JETSTREAM G3 System in patients with moderate to severely calcified peripheral artery disease.
News outlets report on the political dilemma involved with Provenge — a cancer drug — as well as the impact that Makena — the medicine that can prevent preterm births — could have on the nation's high health care costs.
Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.
› Verified 1 days ago
Anastasia V Benoit, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 905 W 124th Ave Ste 170, Westminster, CO 80234 Phone: 303-442-6647 Fax: 303-442-2696 | |
Lawrence Fred Barfield, DO Dermatology Medicare: Not Enrolled in Medicare Practice Location: 10359 Federal Blvd, Suite 210, Westminster, CO 80260 Phone: 303-404-0200 Fax: 303-404-2828 | |
Dr. Carol Ann Alonso, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 905 W 124th Ave Ste 170, Westminster, CO 80234 Phone: 303-442-6647 | |
Dr. Monica Rose Boyle, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9101 Harlan St, Suite 155, Westminster, CO 80031 Phone: 303-426-5000 | |
Sheila Rose Boyle, Dermatology Medicare: Accepting Medicare Assignments Practice Location: 9101 Harlan St, Ste 155, Westminster, CO 80031 Phone: 303-426-5000 |